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ABSTRACT
We conducted a retrospective pharmacokinetic analysis of i.v. busulfan in children undergoing hematopoietic
stem cell transplantation (HSCT) and describe its relation to transplantation outcomes. Forty-five children
(median age, 3 yr) underwent HSCT at The Hospital for Sick Children from April 2003 through January 2006
and received i.v. busulfan every 6 h as part of their conditioning regimen. Initial busulfan doses were based on
actual patient weight: <9 kg, 0.95 mg/kg per dose; 9-16 kg, 1.2 mg/kg per dose; 16-23 kg, 1.1 mg/kg per dose;
24-34 kg, 0.95 mg/kg per dose; >34 kg, 0.8 mg/kg per dose. Plasma busulfan concentrations were obtained
after the first dose. The fourth and subsequent busulfan doses were adjusted to achieve an area under the
concentration versus time curve (AUC) of 900-1500 M · min. Development of hepatic venous occlusive
disease (HVOD; modified Baltimore criteria) and engraftment (absolute neutrophil count >0.5  109/L) were
evaluated. Busulfan pharmacokinetic parameters were calculated using 1-compartment methods. Mean busul-
fan pharmacokinetic parameters were maximum concentration (Cmax; 4.7  0.75 M), volume of distribution
at steady state (0.68  0.17 L/kg), elimination rate constant (0.0051  0.0010 min1), total body clearance
(3.5  1.23 mL/[min · kg]), and AUC (1271  280 M · min). Mean volume of distribution at steady state was
larger in children <1 yr of age (0.77  0.24 vs 0.64  0.11 L/kg; P  .040) and children <4 yr of age (0.73  0.18
vs 0.60 0.11 L/kg; P .001) than in older children. Compared with older children, mean weight-adjusted total
body clearance was higher in children <4 yr of age (3.8  1.40 versus 3.0  0.76 mL/[min · kg]). HVOD was
diagnosed in 8 children (18%), including 4 children <1 yr of age. Children who developed HVOD achieved a
lower Cmax than did those without HVOD (4.2  0.68 versus 4.8  0.73 M; P  .035). Other than Cmax, no
association was observed between busulfan disposition and development of HVOD in children for whom i.v.
busulfan doses were adjusted to achieve a target AUC. The influence of factors other than busulfan disposition
on transplantation outcomes, such as genetic polymorphisms, should be evaluated.
© 2007 American Society for Blood and Marrow Transplantation
KEY WORDS
Hematopoietic stem cell transplantation ● Children ● Busulfan ● Infants ● Pharmacokinetics
p
s
mNTRODUCTION
High-dose busulfan is widely used in pediatric
ematopoietic stem cell transplantation (HSCT) pre- carative regimens. In adults, a relation has been de-
cribed between systemic exposure to busulfan, as
easured by the area under the busulfan plasma con-
entration versus time curve (AUC) or steady state
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T. Schechter et al.308oncentration (Css), and certain transplantation out-
omes. Low systemic exposure has been associated
ith engraftment failure in some settings, whereas
igh systemic exposure has been associated with he-
atic veno-occlusive disease (HVOD) [1-3], more re-
ently termed “sinusoidal obstruction syndrome” [4].
hese relations are inﬂuenced by factors such as un-
erlying diagnosis because adults with chronic my-
logenous leukemia (CML) have tolerated high sys-
emic exposure to busulfan without an increased risk
f HVOD [5].
Acknowledging the large interpatient variability in
pparent busulfan clearance [6], especially in younger
hildren, individualization of busulfan doses has been
ecommended to obtain optimal dose intensity to
chieve engraftment and avoid relapse and toxicity [7].
haracterization of busulfan pharmacokinetic dispo-
ition after oral administration is complicated by its
elayed and erratic absorption [8]. Moreover, emesis
nd the subsequent replacement of vomited tablets
ften result in difﬁculty in estimating AUC, even if
umerous samples are available.
Disposition of busulfan is more predictable after
.v. administration because the variability resulting
rom absorption and the ﬁrst-pass effect is eliminated.
.V. busulfan also offers the practical advantages of not
equiring the use of nasogastric tubes to administer
he drug to uncooperative patients, particularly chil-
ren, and obviates replacement of vomited doses.
urther, HVOD has been shown to occur less fre-
uently in adult patients who received i.v. busulfan
dministration compared with those receiving oral
herapy [9].
The primary objective of this study was to describe
he pharmacokinetic disposition of busulfan after i.v.
dministration to infants and children before HSCT.
e also evaluated the relations between busulfan
harmacokinetic parameters and transplantation out-
omes, speciﬁcally HVOD, engraftment failure, and
verall survival, in this group of patients.
ETHODS
This study was approved by our institution’s re-
earch ethics board. Children 18 yr of age who
nderwent HSCT from April 1, 2003 to January 30,
006 at The Hospital for Sick Children (Toronto,
ntario, Canada) and received i.v. busulfan as part of
heir conditioning regimen were studied. Data were
ollected from patients’ health records and/or phar-
acy records including demographic information, re-
eipt of previous antineoplastic treatment, HSCT
ate, type of conditioning regimen, busulfan ﬁrst
ose, plasma busulfan concentrations, busulfan dose
djustment (if any), time of neutrophil engraftment,
iagnosis of HVOD, and survival at day 100 after oransplantation. Hepatic function was considered to
e impaired if transaminase values were 3 times the
pper limit of normal for age and serum bilirubin
alues were above the upper limit of normal for age.
usulfan Dose and Dose Adjustment
Intravenous busulfan was dosed based on actual
ody weight as outlined in Table 1. The ﬁrst dose was
dministered as a 2-h infusion, including the line
ush, using an i.v. infusion pump on day9 at 0300 h.
erum busulfan levels were obtained at 0, 15, 30, 60,
20, 180, and 240 min after infusion of the ﬁrst dose.
erum busulfan concentrations were assayed by gas
hromatography with electron capture detection
10,11]. The coefﬁcient of variation of the assay is
.8%-6.0%. For clinical purposes, busulfan AUC
as calculated for each patient using the trapezoidal
ule [12]. Because the relation between busulfan
ose and AUC is linear, the following equation was
sed to determine an adjusted dose: adjusted dose 
test dose  target AUC)/test dose AUC. The intended
cceptable AUC range was 900-1500 M · min
13,14]; the clinical team aimed for AUC values at the
igh or low end of this range at their discretion. The
djusted busulfan dose was given from the fourth dose
n such that patients generally received 3 nonadjusted
oses followed by 13 adjusted doses. The busulfan
UC determination was repeated after dose adjust-
ent and the dose was readjusted at the discretion of
he clinical team.
For the purpose of this study, busulfan pharmaco-
inetic parameters were calculated using a 1-compart-
ent, ﬁrst-order model (WinNonLin 4.1, Pharsight
orp, Mountainview, Calif). The cumulative AUC
as calculated by multiplying the number of doses
dministered by the AUC each busulfan dose pro-
uced or was predicted to produce.
epatic Veno-occlusive Disease
The diagnosis of HVOD was determined by the
linical team and retrospectively conﬁrmed by a study
nvestigator (TS) using the modiﬁed Baltimore diag-
ostic criteria [15]. For the purposes of this study,
able 1. Initial i.v. Busulfan Dosage*
Child’s Actual
Weight (kg)
Initial Busulfan Dose
(mg/kg per dose)
No. of
Children
<9 1 9
9 to <16 1.2 5
16 to <23 1.1 2
23 to <34 0.95 4
>34 0.8 4
Busulfan was given i.v. over 2 h every 6 h for 16 doses. The fourth
and subsequent doses were adjusted if necessary to achieve a
target AUC of 900-1500 M · min.nly patients who met diagnostic criteria were deemed
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Pharmacokinetics of i.v. Busulfan and Clinical Outcomes in Children 309o have HVOD. Severe HVOD was deﬁned as
VOD that did not resolve before day 100 and/or
as fatal [16]. HVOD was considered to be moderate
f it required treatment and/or patients developed ad-
erse effects from liver disease; mild HVOD was self-
imited and required no treatment.
eutrophil Engraftment
Neutrophil engraftment was deﬁned as the ﬁrst of
consecutive days on which the absolute neutrophil
ount was 0.5  109/L.
ransplant-related Mortality
Death during the ﬁrst 100 d after HSCT was
ocumented as early mortality.
tatistical Analysis
Descriptive statistics were used to calculate mean
harmacokinetic parameters. Differences between
ubgroups were evaluated by nonparametric tests.
omparisons of the incidence of HVOD between
roups were made using the Fisher exact test. The a
riori level of signiﬁcance for all statistical tests was
05. Statistical analysis was performed with SPSS
3.0.1. (SPSS, Inc, Chicago, Ill).
ESULTS
A total of 47 children who underwent HSCT
uring the study period received i.v. busulfan as part
f their conditioning regimen. Two children were
xcluded from analysis because a low busulfan dose
as given as part of a reduced intensity conditioning
rotocol. Demographic data for the remaining 45 pa-
ients, including 13 infants, are presented in Table 2.
our patients had impaired liver function at time of
SCT. Abnormalities observed in these patients were
levations in alanine aminotransferase (2 patients), in
nconjugated bilirubin (1 patient), and in alanine and
spartate aminotransferases (1 patient). Immediately
efore HSCT, 2 patients who underwent transplanta-
ion for beta-thalassemia had hepatic function test and
epatic iron stores values within the normal range for
ge. The third patient with beta-thalassemia had high
iver iron stores (3 mg/g liver, dry weight) and high
erum ferritin concentrations (1969 g/L) 6 wk before
SCT.
Forty-three patients received 16 doses of busulfan
iven every 6 h for 4 d. Inadvertent breakage of the
entral venous catheter of 2 patients necessitated oral
dministration of busulfan until the catheter was re-
aired. These patients received a total of 12 and 11 i.v.
usulfan doses and 4 and 5 oral busulfan doses, re-
pectively.
In 42 patients, busulfan was followed by cyclo-
hosphamide. On average, the ﬁrst cyclophosphamide tose was given 13.7 h (range, 11.8-16.3 h) after the
nitiation of the last busulfan dose. No HVOD pro-
hylaxis was given. To prevent busulfan-induced sei-
ures, all patients received phenytoin. A loading phe-
ytoin dose of 20 mg/kg (maximum, 1 g/dose) was
iven by mouth or i.v. 24 h before the ﬁrst busulfan
ose was due. Maintenance phenytoin dosing was ini-
iated 8 h after the loading dose and continued until
4 h after the last busulfan dose. No patient demon-
trated seizures during or within 24 h of busulfan
dministration.
usulfan Dose and Pharmacokinetics
Twenty-ﬁve children (56%), including 7 infants,
chieved an AUC within the target range after admin-
stration of the initial busulfan dose (median, 1209
M · min; range, 924-1474 M · min). Dose eleva-
ions of 25%-51% (median, 27%) were made in 7
atients, including 3 infants. The initial AUC values
f these patients were 772-1014 M · min (median,
01 M · min). An initial AUC 1500 or 1350
M · min was achieved in 9 and 14 children, respec-
able 2. Demographic Data for 45 Children Who Received i.v.
usulfan during the Study Period
atient age (yr), mean/median/range 5.1/3.0/0.25-16.2
atient weight (kg), mean/median/range 23.4/13.7/4.8-108.7
ale:female 26:19
iagnosis (no. of patients)
AML 10
Immune deficiency syndrome 8
Histiocytosis 4
CML 4
Hurler syndrome 4
Beta-thalassemia 3
Medulloblastoma 3
Osteopetrosis 2
Wiskott-Aldrich syndrome 2
Other 5
onor type (no. of patients)
Matched related 15
Mismatched related 3
Matched unrelated 15
Mismatched unrelated 2
Matched cord 3
Mismatched cord 3
Autologous 3
Haploidentical 1
onditioning regimen (no. of patients)
Bu, Cy 26
Bu, Cy, ATG 11
Bu, Cy, Eto 4
Bu, thiotepa 3
Bu, Cy, ATG, melphalan 1
VHD prophylaxis (no. of patients)
Cyclosporine and methotrexate 26
Cyclosporine and methylprednisolone 13
Cyclosporine alone 3
None (autologous transplants) 3
u indicates i.v. busulfan; Cy, cyclophosphamide; Eto, etoposide.ively. Dose reductions of 10%-26% (median, 15%)
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T. Schechter et al.310ere made in 12 patients, including 3 infants. The
nitial AUC values of these patients were 1301-1932
M · min (median, 1629 M · min). The ﬁrst busul-
an dose administered to 1 patient was higher than
ntended. This patient’s adjusted busulfan dose was
igher than the initial dose originally prescribed. One
atient underwent 2 AUC determinations.
Mean busulfan pharmacokinetic parameters (AUC,
aximum plasma concentration [Cmax], total body clear-
nce [TBC], and volume of distribution at steady state
Vss]) calculated after each patient’s ﬁrst busulfan dose
re presented in Table 3. Children 1 yr of age were
ound to have higher mean Vss values when corrected
or body weight compared with older children (0.77
ersus 0.64 L/kg; P  .040). This difference was also
een in children 4 yr of age compared with older
hildren (0.73 versus 0.60 L/kg; P  .001). Weight-
djusted TBC was signiﬁcantly higher in children 4
r of age compared with older children (3.8 versus 3.0
L/[min · kg]; P .029). However, TBC adjusted for
ody surface area was signiﬁcantly lower in children
1 yr of age (76 versus 99 mL/[min · m2]; P  .028)
nd 4 yr of age (84 versus 103 mL/[min · m2]; P 
009) compared with older children.
epatic Veno-occlusive Disease
Eight patients (18%) developed HVOD (mean
ge, 7.5 yr; age range, 0.5-16.2 yr). Six patients
2 infants) had moderate HVOD and 2 infants had
evere HVOD. Neither infants (4 of 13 versus 4 of 32;
 .20) nor children 4 yr of age (4 of 26 versus 4 of
9; P  .70) were more likely to develop HVOD than
ere older children. None of the children with im-
aired liver function at the start of conditioning and
either of the 2 children who had received several oral
usulfan doses during conditioning because of mal-
unction of their central venous catheter developed
VOD. The child with beta-thalassemia and high
iver iron and serum ferritin concentrations before
SCT did not develop HVOD. Diagnoses before
SCT for the 8 patients with HVOD were beta-
halassemia (2 children), hemophagocytic lymphohis-
iocytosis (1 infant and 1 child), Hurler syndrome (2
nfants), myelodysplastic syndrome (1 child), and se-
ere combined immunodeﬁciency (1 infant). All pa-
ients with HVOD were conditioned with a regimen
ontaining cyclophosphamide. Patients presented
ith abdominal pain, hyperbilirubinemia, and weight
ain (2 patients), hepatomegaly (2 patients), or in-
reased abdominal girth (4 patients). All patients re-
eived supportive treatment of HVOD including ﬂuid
estriction and furosemide. Ursodiol, deﬁbrotide, and
-acetylcysteine were also given to 6, 7, and 1 pa-
ients, respectively. Two patients with severe HVOD
ied on days 35 and 55 from multiorgan failure
espite aggressive intensive care. Ta C m ke Ha Vs
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Pharmacokinetics of i.v. Busulfan and Clinical Outcomes in Children 311Children who developed HVOD achieved a lower
max than did those who did not develop HVOD (4.2
ersus 4.8 M; P  .035). No other statistically sig-
iﬁcant differences in busulfan disposition parameters
elimination rate constant, Vss, TBC, weight-adjusted
BC, body surface area-adjusted TBC, AUC, or cu-
ulative AUC) were observed between children who
eveloped HVOD and those who did not. The
nterval between the last busulfan dose and the ﬁrst
yclophosphamide dose was also similar in children
ho did and did not develop HVOD (13.8 vs 13.6 h;
 .65).
ngraftment and Survival
All patients demonstrated engraftment. Median
ime to neutrophil engraftment was 17 d (median,
6 d; range, 8-36 d).
Overall survival at day 100 was 91% (41 of 45).
wo children died as a result of HVOD and 2 because
f multiorgan failure.
ISCUSSION
We have described the pharmacokinetic disposi-
ion of busulfan after i.v. administration to 45 chil-
ren, including 13 infants, undergoing HSCT. We
bserved no relation between development of HVOD
nd busulfan TBC or AUC in children receiving in-
ividualized i.v. busulfan doses. However, children
ho developed HVOD had a signiﬁcantly lower
usulfan Cmax than did children who did not develop
VOD.
Our observations regarding busulfan disposition
n children are consistent with the ﬁndings of other
nvestigators [17-22] (Table 4). Age-related differ-
nces in busulfan disposition were ﬁrst identiﬁed after
ral administration of the drug [23]; however, vari-
bility in absorption likely obscured some of this ef-
ect. Examination of values reported in the literature
fter oral busulfan administration indicates that
eight-adjusted TBC and Vss are lower and half-life
s longer in adults than in children [24-28]. Children
ave been shown to conjugate busulfan more efﬁ-
iently than adults; thus, after oral administration to
hildren, a larger proportion of the busulfan dose may
ndergo glutathione conjugation during passage
hrough the intestinal wall and in the liver [29,30].
ppreciation of age-related differences in busulfan
isposition after i.v. administration within the pediat-
ic age group has been hampered by the limited num-
er of very young children studied. However, existing
ata indicate that busulfan TBC is higher in young
hildren than in adolescents. Tran et al [31] included
infant in their study sample; these investigators iden-
iﬁed higher mean weight-adjusted busulfan TBC in
hildren 6 yr compared with children 6 yr of age. Ta Zw O
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T. Schechter et al.312imilarly, Zwaveling et al [17] observed a higher mean
eight-adjusted TBC in children 4 yr of age com-
ared with children 4 yr of age. A close examination
f the data provided by Dalle et al [20] indicates that
he mean weight-adjusted busulfan TBC was signiﬁ-
antly higher in infants 6 mo of age compared with
nfants 6 mo of age. Recently, Kletzel et al [22]
escribed busulfan pharmacokinetic disposition after
.v. administration to 26 children. No assessment of
ge-related differences in disposition was made.
In our study, we observed signiﬁcant differences in
usulfan Vss between younger (1 yr and 4 yr) and
lder (1 yr and 4 yr) children. However, these
ifferences did not translate into differences in busul-
an weight-adjusted TBC between infants and older
hildren, although signiﬁcant differences in TBC
ere observed between children 4 yr of age and
lder children. Other investigators have observed a
elatively larger liver volume normalized to body
eight in younger children [31]. This may explain the
eed for higher doses of drugs that are primarily
leared by the liver, such as busulfan, when expressed
s milligrams per kilogram in children. Interestingly,
e found body surface area-adjusted TBC to be lower
n younger than in older children.
Values of busulfan pharmacokinetic parameters
ay differ among studies depending on the type of
eizure prophylaxis administered. In cohorts such as
urs in which phenytoin, an enzyme inducer, is ad-
inistered, one might expect higher values for busul-
an TBC and lower values for half-life. However,
guyen et al [32] observed no evidence of enzyme
nduction in 120 adults receiving i.v. busulfan. That is,
o change in busulfan clearance from busulfan dose 1
o dose 13 was observed. The contribution of phenyto-
n to the interpatient variability in busulfan disposition
s therefore unlikely to be signiﬁcant, at least when
usulfan is given i.v.
The incidence of HVOD in our patients was 18%.
his is in agreement with our institution’s and others’
revious experience with oral busulfan in children
33-35]. Several risk factors for the development of
VOD after HSCT have been identiﬁed including
enetic polymorphisms and mutations; iron overload;
re-existing liver damage; history of pancreatitis; prior
SCT; underlying malignant disease; donor type;
onditioning with busulfan, cyclophosphamide, or
acarbazine; and GVHD prophylaxis with cyclospor-
ne and methotrexate [36-39]. Children who devel-
ped HVOD in our study all received i.v. busulfan
ollowed by cyclophosphamide. Interestingly, only 1
f our patients with HVOD had received antineoplas-
ic or radiation therapy before HSCT. This patient
ad myelodysplastic syndrome and had been treated
ith cytarabine for 5 d. Myelodysplastic syndrome has
een identiﬁed as a risk factor for developing HVOD
9]. We therefore speculate that the underlying diag- iosis may have increased this patient’s risk of devel-
ping HVOD. Two of 3 patients with beta-thalasse-
ia developed HVOD. The degree of siderosis on
iver biopsy and serum ferritin concentrations, which
eﬂect severity of disease, have been reported to be
ssociated with the occurrence of HVOD [40]. How-
ver, the patients in our cohort who developed
VOD did not have signs of signiﬁcant liver involve-
ent immediately before HSCT.
The association between high busulfan dose in-
ensity as measured by Css or AUC and HVOD is well
ccepted, at least in adults given oral busulfan [3,6].
he existence of this association in children is contro-
ersial, although generally accepted [13,33,40,41].
assal et al [42] observed a trend toward an increased
ncidence of HVOD in 57 children who achieved a
igher AUC after oral busulfan administration. Of the
4 children who developed HVOD, 12 achieved an
UC 1500 M · h. Bolinger et al [43] also observed
trend toward a relation between increasing Css and
n increased incidence of regimen-related toxicity af-
er oral administration of busulfan. The relation be-
ween busulfan pharmacokinetics parameters and
VOD was not speciﬁcally addressed in this study.
even of the 32 children studied achieved a Css 900
g/mL (AUC 1300 M · h). Conversely, McCune
t al [14] did not observe an association between high
ss and regimen-related toxicity in 53 children receiv-
ng oral busulfan. Only 1 of 10 children who achieved
Css 900 ng/mL had severe regimen-related toxic-
ty. HVOD was not speciﬁcally addressed.
We observed an inverse relation between busulfan
max and development of HVOD. That is, children
ho developed HVOD achieved a lower Cmax than
id children who did not develop HVOD. This dif-
erence, although of statistical signiﬁcance, may be of
arginal clinical value. Recent explorations of clinical
utcomes after administration of once-daily i.v. busul-
an to adults [26,27,44] and children [22] undergoing
SCT have shown no detrimental effect associated
ith the high peak plasma busulfan concentrations
chieved as a result of this dosing regimen.
Intravenous busulfan administration to adults has
een reported to reduce the incidence of HVOD to as
ow as 8% compared with that seen after conditioning
hat includes oral busulfan [9,45]. However, neither
omparative study to date adjusted busulfan doses to
chieve a target AUC or Css and in 1 study the AUCs
chieved were low. Patients who have high busulfan
BC and presumably high intrahepatic busulfan con-
entrations may be at increased risk of HVOD regard-
ess of the route of administration. Srivastava et al [40]
eported a signiﬁcantly higher incidence of HVOD in
hildren who had a weight-adjusted apparent oral
usulfan TBC 6.2 mL/(min · kg) and/or the gluta-
hione S-transferase (GST) M1-null genotype. No
nfants were included in this study; all patients re-
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djusted busulfan TBC was 6.2 mL/(min · kg) in
nly 1 of our patients (9.3 mL/[min · kg]), an infant
ho did not develop HVOD. Infants generally have
igher weight-adjusted busulfan clearances than do
lder children. They, like patients with the GST null
enotype, may be at higher risk of developing HVOD
ecause they may have higher intrahepatic busulfan
oncentrations. The lack of a statistically signiﬁcant
ifference in the number of infants who developed
VOD compared with older children may result from
he small overall sample or the small number of in-
ants included in our study compared with the number
f older children. A larger number of infants must be
tudied to fully evaluate age-related differences in
usulfan clearance and the incidence of HVOD.
Current data regarding the incidence of HVOD
fter administration of i.v. busulfan to children are
onﬂicting. Some studies in children have reported
hat i.v. busulfan is well tolerated by children, without
ny documented cases of HVOD [18,19]. Busulfan
oses were individualized in 1 of these studies [19] and
signiﬁcant proportion of children in the second
ailed to achieve a busulfan AUC in the target range.
ur ﬁndings compare with those of Zwaveling et al
17] who observed an incidence of HVOD of 8 of 31
26%) in children after administration of individual-
zed i.v. busulfan doses. Neither we nor other inves-
igators have identiﬁed a relation between busulfan
isposition parameters and transplantation outcomes
ncluding HVOD in children after i.v. busulfan ad-
inistration. However, it must be acknowledged that
he ability to identify such relations may be blunted by
usulfan dose adjustment and/or administration of
ow doses that ensure that the busulfan AUC remains
1500 M · min. In addition, evaluation of GST M1
enotype in our patients was beyond the scope of this
ork and therefore we cannot determine its effect on
ur present ﬁndings.
In summary, our data suggest that the prevalence
f HVOD in children is lower after i.v. administration
f busulfan than that seen after oral administration of
he drug, but not dramatically so. Children with
VOD had a lower Cmax than did children without
VOD. We did not observe a relation between any
ther busulfan pharmacokinetic parameter and
VOD. Although the hypothesis that infants may be
t higher risk of busulfan-induced HVOD than older
hildren should be explored further, the inﬂuence of
actors other than busulfan disposition on transplan-
ation outcomes, such as genetic polymorphisms,
hould also be evaluated.
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